-transparent.png){kind=logo}
Renal failure is a frequent but inconstant complication of myeloma related to light chain excretion. Since it has been suggested that cationic light chains (lc) are most likely to induce renal damage, we have studied the isoelectric point (pI) of light chains produced by 17 patients with myeloma and related the results to the type and severity of renal damage assessed clinically and pathologically. In order to do so, we have applied immunoenzymatic techniques which allow identification of light chain types as well as measurement of pI without prior purification. Ten of fifteen patients with renal failure produced lambda light chains. There was no simple relationship between the isoelectric point and nephrotoxicity. However, light chains with the lowest pI observed in this series were associated with normal renal function in two cases and with acute reversible but severe renal failure requiring dialysis in five cases. By contrast, pI values above 6.0 observed in the remaining patients were associated with moderate renal failure in six patients with recently diagnosed myeloma and with irreversible renal failure, and in two patients in whom myeloma had been evolutive for several years. We thus suggest that further pI measurements may help to identify light chains with different nephrotoxic potentials.
C Melcion, and
B Mougenot, and
B Baudouin, and
P Ronco, and
L Moulonguet-Doleris, and
P Vanhille, and
M Beaufils, and
L Morel-Maroger, and
P Verroust, and
G Richet
February 1981,
La Nouvelle presse medicale,
C Melcion, and
B Mougenot, and
B Baudouin, and
P Ronco, and
L Moulonguet-Doleris, and
P Vanhille, and
M Beaufils, and
L Morel-Maroger, and
P Verroust, and
G Richet
February 1984,
Clinical science (London, England : 1979),
C Melcion, and
B Mougenot, and
B Baudouin, and
P Ronco, and
L Moulonguet-Doleris, and
P Vanhille, and
M Beaufils, and
L Morel-Maroger, and
P Verroust, and
G Richet
February 1977,
Journal of immunology (Baltimore, Md. : 1950),
C Melcion, and
B Mougenot, and
B Baudouin, and
P Ronco, and
L Moulonguet-Doleris, and
P Vanhille, and
M Beaufils, and
L Morel-Maroger, and
P Verroust, and
G Richet
February 1971,
Experientia,
C Melcion, and
B Mougenot, and
B Baudouin, and
P Ronco, and
L Moulonguet-Doleris, and
P Vanhille, and
M Beaufils, and
L Morel-Maroger, and
P Verroust, and
G Richet
July 1976,
The Journal of experimental medicine,
C Melcion, and
B Mougenot, and
B Baudouin, and
P Ronco, and
L Moulonguet-Doleris, and
P Vanhille, and
M Beaufils, and
L Morel-Maroger, and
P Verroust, and
G Richet
January 1986,
The American journal of medicine,
C Melcion, and
B Mougenot, and
B Baudouin, and
P Ronco, and
L Moulonguet-Doleris, and
P Vanhille, and
M Beaufils, and
L Morel-Maroger, and
P Verroust, and
G Richet
November 2013,
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia,
C Melcion, and
B Mougenot, and
B Baudouin, and
P Ronco, and
L Moulonguet-Doleris, and
P Vanhille, and
M Beaufils, and
L Morel-Maroger, and
P Verroust, and
G Richet
April 1990,
Proceedings of the National Academy of Sciences of the United States of America,
C Melcion, and
B Mougenot, and
B Baudouin, and
P Ronco, and
L Moulonguet-Doleris, and
P Vanhille, and
M Beaufils, and
L Morel-Maroger, and
P Verroust, and
G Richet
January 1989,
Journal of clinical pathology,
C Melcion, and
B Mougenot, and
B Baudouin, and
P Ronco, and
L Moulonguet-Doleris, and
P Vanhille, and
M Beaufils, and
L Morel-Maroger, and
P Verroust, and
G Richet
August 2015,
Journal of clinical medicine research,
